Figure 4.
Compared SVR rates of pan-genotypic DAAs (G/P and SOL/VEL) regimens in end-stage renal disease patients with HCV infection. The mean pooled advent events per regimen with 95% CI. G/P, SOF, Sofosbuvir; VEL, Velpatasvir.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.